Biomarkers to predict prognosis and response to checkpoint inhibitors.
Biomarkers to predict prognosis and response to checkpoint inhibitors.
复制标题
DOI：
10.1007/s10147-017-1122-1
复制
发表时间：
2017-08
影响因子：
3.3
通讯作者：
Yonese J
中科院分区：
文献类型：
--
作者：
Yuasa T;Masuda H;Yamamoto S;Numao N;Yonese J
Nivolumab是一种选择性抑制程序性死亡1（PD-1）免疫检查点分子的全人源免疫球蛋白（IG）G4抗体，最近在日本上市用于治疗肾细胞癌（RCC）。基于其在III期Checkmate 025试验中证明的有希望的抗肿瘤疗效和可管理的安全性特征，nivolumab疗法正在转移性RCC临床实践中迅速引入。atezolizumab是一种人源化抗PD-配体1（PD-L1）单克隆IgG 1抗体，其Ia期研究也显示了优异的治疗结果。因此，迫切需要鉴定生物标志物来预测检查点抑制剂治疗的反应和副作用。在这篇综述中，我们介绍了目前免疫检查点抑制剂治疗的候选生物标志物。基于疗效机制，新抗原的数量和主要组织相容性复合体分子的表达是强有力的候选生物标志物。尽管存在各种干扰因素，但PD-L1表达可被视为潜在的生物标志物。在临床因素方面，检查血清临床因素和不良事件的严重程度。虽然在前瞻性研究中的进一步实施是必要的，如果验证，这些生物标志物可用于测量治疗反应和设计治疗策略转移性RCC。
Nivolumab is a fully human immunoglobulin (Ig) G4 antibody that selectively inhibits the programmed death 1 (PD-1) immune checkpoint molecule, and has recently been launched for the treatment of renal cell cancer (RCC) in Japan. Based on its promising anti-tumor efficacy and manageable safety profile demonstrated in the phase III Checkmate 025 trial, nivolumab therapy is rapidly being introduced in metastatic RCC clinical practice. The phase Ia study of atezolizumab, which is a humanized anti-PD-ligand 1 (PD-L1) monoclonal IgG1 antibody, also demonstrated excellent treatment results. The identification of biomarkers to predict the response and side-effects of checkpoint inhibitor therapy is thus urgently needed. In this review, we introduce the current candidate biomarkers of immune checkpoint inhibitor therapy. Based on the mechanism of efficacy, the number of neoantigens and expression of major histocompatibility complex molecules are strong candidate biomarkers. Despite the various interference factors, PD-L1 expression can be considered a potential biomarker. In terms of clinical factors, serum clinical factors and severity of adverse events are examined. Although further implementation in prospective studies is necessary, if validated, these biomarkers can be utilized to measure therapeutic response and design treatment strategies for metastatic RCC.
登录
查看更多内容
影响因子：
51.1
作者：
Ko, Jenny J.;Xie, Wanling;Heng, Daniel Y. C.
通讯作者：
Heng, Daniel Y. C.
影响因子：
168.9
作者：
Escudier, Bernard;Pluzanska, Anna;Moore, Nicola
通讯作者：
Moore, Nicola
影响因子：
16.6
作者：
Johnson DB;Estrada MV;Salgado R;Sanchez V;Doxie DB;Opalenik SR;Vilgelm AE;Feld E;Johnson AS;Greenplate AR;Sanders ME;Lovly CM;Frederick DT;Kelley MC;Richmond A;Irish JM;Shyr Y;Sullivan RJ;Puzanov I;Sosman JA;Balko JM
通讯作者：
Balko JM
PD-1，PD-1配体的关联以及肿瘤免疫微环境的其他特征与抗PD-1治疗的响应。
DOI：
10.1158/1078-0432.ccr-13-3271
发表时间：
2014-10-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Taube JM;Klein A;Brahmer JR;Xu H;Pan X;Kim JH;Chen L;Pardoll DM;Topalian SL;Anders RA
通讯作者：
Anders RA
影响因子：
45.3
作者：
Daud, Adil I.;Wolchok, Jedd D.;Hamid, Omid
通讯作者：
Hamid, Omid